{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:28:05Z","timestamp":1794932885326,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA150220"],"award-info":[{"award-number":["CA150220"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["RO1 CA198138"],"award-info":[{"award-number":["RO1 CA198138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002879","name":"Canadian HIV Trials Network, Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["399244"],"award-info":[{"award-number":["399244"]}],"id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/s41419-018-1206-5","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T14:34:01Z","timestamp":1542638041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["BAP1 regulates different mechanisms of cell death"],"prefix":"10.1038","volume":"9","author":[{"given":"El Bachir","family":"Affar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"1206_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.semdp.2006.08.002","volume":"23","author":"M Carbone","year":"2006","unstructured":"Carbone, M. & Bedrossian, C. W. The pathogenesis of mesothelioma. Semin. Diagn. Pathol. 23, 56\u201360 (2006).","journal-title":"Semin. Diagn. Pathol."},{"key":"1206_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/atm.2017.04.06","volume":"5","author":"SA Emri","year":"2017","unstructured":"Emri, S. A. The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad. Ann. Transl. Med 5, 239 (2017).","journal-title":"Ann. Transl. Med"},{"key":"1206_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022\u20131025 (2011).","journal-title":"Nat. Genet."},{"key":"1206_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-179","volume":"10","author":"M Carbone","year":"2012","unstructured":"Carbone, M. et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med 10, 179 (2012).","journal-title":"J. Transl. Med"},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","volume":"11","author":"M Carbone","year":"2016","unstructured":"Carbone, M. et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J. Thorac. Oncol. 11, 1246\u20131262 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"e1005633","DOI":"10.1371\/journal.pgen.1005633","volume":"11","author":"M Carbone","year":"2015","unstructured":"Carbone, M. et al. Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. PLoS Genet. 11, e1005633 (2015).","journal-title":"PLoS Genet."},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1128\/MCB.00396-10","volume":"30","author":"H Yu","year":"2010","unstructured":"Yu, H. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol. Cell. Biol. 30, 5071\u20135085 (2010).","journal-title":"Mol. Cell. Biol."},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1126\/science.1221711","volume":"337","author":"A Dey","year":"2012","unstructured":"Dey, A. et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337, 1541\u20131546 (2012).","journal-title":"Science"},{"key":"1206_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.1309085110","volume":"111","author":"H Yu","year":"2014","unstructured":"Yu, H. et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. Natl. Acad. Sci. USA\n                           111, 285\u2013290 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1206_CR10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","volume":"546","author":"A Bononi","year":"2017","unstructured":"Bononi, A. et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 546, 549\u2013553 (2017).","journal-title":"Nature"},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/cdd.2017.95","volume":"24","author":"A Bononi","year":"2017","unstructured":"Bononi, A. et al. Germline BAP1 mutations induce a Warburg effect. Cell death Differ. 24, 1694\u20131704 (2017).","journal-title":"Cell death Differ."},{"key":"1206_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 20, 1181\u20131192 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.molcel.2014.03.002","volume":"54","author":"N Mashtalir","year":"2014","unstructured":"Mashtalir, N. et al. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol. Cell 54, 392\u2013406 (2014).","journal-title":"Mol. Cell"},{"key":"1206_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06854-2","volume":"9","author":"S Daou","year":"2018","unstructured":"Daou, S. et al. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1. Nat. Commun. 9, 4385 (2018).","journal-title":"Nat. Commun."},{"key":"1206_CR15","doi-asserted-by":"publisher","first-page":"28643","DOI":"10.1074\/jbc.M115.661553","volume":"290","author":"S Daou","year":"2015","unstructured":"Daou, S. et al. The BAP1\/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer. J Biol. Chem. 290, 28643\u201328663 (2015).","journal-title":"J. Biol. Chem."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1206-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T15:04:43Z","timestamp":1672671883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1206-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1206-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"29 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None. For full disclosure\u00a0Dr. Carbone declares that he\u00a0has pending patent applications on BAP1, a patent using anti-HMGB1 monoclonal antibody or other HMGB1 antibodies as a novel mesothelioma therapeutic strategy, Patent No.: 9,561,274 issued, and a patent HMGB1 as a biomarker for asbestos exposure and mesothelioma early detection Application No.: 14\/123,722 Patent No.: 9,244,074. Dr. Carbone is a board certified Pathologist and provides consultation for mesothelioma expertise and diagnosis, including paid medical-legal consulting. E.B.A. has nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1151"}}